ReviewInternational immunopharmacology2021
Coronavirus disease-2019: A review on the disease exacerbation via cytokine storm and concurrent management.
Review in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Use of steroids in COVID-19 patients: A meta-analysis.European journal of pharmacology · 2022Pooled it
- Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19.Frontiers in immunology · 2022Trial
- A Review: Can Cytokines Induce Vascular Inflammation as a Sequela of Viral Infections?Health science reports · 2025Article
- Addressing the Health Risks Posed by Adenovirus: A Perspective on Strategies for Prevention and Management.Health science reports · 2025Article
- The pressing need for study on the effects of Mpox on the progression of vascular inflammation: A well-timed call.Health science reports · 2024Article
- Immunization against dengue virus infection is coercive: A timely call.Health science reports · 2024Article
- JN.1: The Present Public Health Concern Pertains to the Emergence of a Novel Variant of COVID-19.Environmental health insights · 2024Article
- Present Public Health Concern: Could the Transmission of the JN.1 Variant of COVID-19 Place Bangladesh at Risk of Transmitting the Disease?Environmental health insights · 2024Article
- Chinese Pneumonia Outbreak 2023: Is It Reasonable to Be Concerned If the Illness is a Novel Strain of Disease X?Environmental health insights · 2024Article
- Only COVID-19 and not all infectious diseases are of concern: A timely observation.Health science reports · 2023Article
- An observation: Could the spread of Adenovirus in South Asia pose a hazard to global public health?Health science reports · 2023Article
- The risk of SARS-CoV-2 infection through sexual contact should be investigated: A timely call.Immunity, inflammation and disease · 2023Article
- Host-Based Treatments for Severe COVID-19.Current issues in molecular biology · 2023Review
- Effective Preventative Measures are Essential to Lower Disease Burden From Dengue and COVID-19 Co-infection in Bangladesh.Environmental health insights · 2023Article
- Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever.Pharmacological research · 2022Article
- Dietary Salt Can Be Crucial for Food-Induced Vascular Inflammation.Clinical pathology (Thousand Oaks, Ventura County, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Setting up treatment strategies is the highest concern today to reduce the fatality of COVID-19. Due to a very new kind of virus attack, no specific treatment has been discovered to date. The most crucial way to dominate the disease severity is now the repurposing of drugs. In this review, we focused on the current treatment approaches targeting the crucial causative factors for the disease burden through cytokine storm or cytokine release syndrome. Several vaccines have been developed and have been applied already for prevention purposes, and several are on the way to be developed, although the effects and side effects are under observation. Presently, regulation of the immune response through intervention treatment methods has been adjusted on the basis of the COVID-19 severity stage and generally includes vaccines, immunotherapies including convalescent plasma and immunoglobulin treatment, monoclonal antibodies, cytokine therapy, complement inhibition, regenerative medicine, and repurposed anti-inflammatory and immune-regulatory drugs. Combination therapy is not acceptable in all respects because there is no concrete evidence in clinical trials or in vivo data. Target-specific drug therapies, such as inhibition of cytokine-producing signaling pathways, could be an excellent solution and thus reduce the severity of inflammation and disease severity. Therefore, gathering information about the mechanism of disease progression, possible goals, and drug efficacy of immune-based approaches to combat COVID-19 in the context of orderly review analysis is consequential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.